Literature DB >> 11328954

Different cytokine expression in cord blood mononuclear cells after stimulation with neonatal sepsis or colonizing strains of Streptococcus agalactiae.

R Berner1, J Csorba, M Brandis.   

Abstract

Streptococcus agalactiae (group B streptococcus, GBS) is the major pathogen of neonatal sepsis. In some newborns, GBS sepsis may have a severe course, including septic shock with a high mortality rate, whereas other newborns are colonized with GBS on their surfaces without any clinical signs of bacterial infection. The reason for this discrepancy is far from clear. We sought, in this study, to compare cytokine expression in cord blood mononuclear cells after stimulation with GBS strains isolated from newborns with sepsis, and strains isolated from newborns without any symptoms of invasive infection. Cord blood mononuclear cells were incubated with either heat-killed bacteria of different strains or lipopolysaccharide, respectively. After 6 and 24 h, cells were harvested and cytokine mRNA-expression was analyzed by reverse-transcriptase PCR. Likewise, supernatants were tested for IL-6 and tumor necrosis factor-alpha concentrations by enzyme immunoassay. When comparing IL-6 and tumor necrosis factor-alpha secretion, there were significantly higher IL-6 levels after stimulation with sepsis than with colonizing isolates. Likewise, mRNA expression of IL-6, IL-1 beta, and IL-12p40 was significantly higher after stimulation with sepsis isolates. This was also true when normalizing to cytokine expression after stimulation with lipopolysaccharide. These findings indicate that the different clinical pictures in response to GBS, either septic infection or colonization, might reflect strain-specific properties. If the respective characteristics can be defined, it might become possible to distinguish by molecular methods potentially "dangerous" from "harmless" strains. Moreover, our findings underline the essential role of these cytokines in the pathogenesis of neonatal GBS sepsis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328954     DOI: 10.1203/00006450-200105000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

2.  Early neonatal streptococcal infection.

Authors:  Krishnamoorthy Niduvaje; Chinnadurai Amutha; Joseph Roy
Journal:  Indian J Pediatr       Date:  2006-07       Impact factor: 1.967

Review 3.  The role of B cells and accessory cells in the neonatal response to TI-2 antigens.

Authors:  Cheri D Landers; R Lakshman Chelvarajan; Subbarao Bondada
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Galectin-3 in cord blood of term and preterm infants.

Authors:  M Demmert; K Faust; M K Bohlmann; B Tröger; W Göpel; E Herting; C Härtel
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

5.  Group B streptococci infection model shows decreased regulatory capacity of cord blood cells.

Authors:  Kriszta Molnar; Hannah Riedel; Julian Schwarz; Stefanie Dietz; Bärbel Spring; Laura Haag; Christian F Poets; Christian Gille; Natascha Köstlin-Gille
Journal:  Pediatr Res       Date:  2022-02-14       Impact factor: 3.756

6.  Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release.

Authors:  Ofer Levy; Rochelle M Jean-Jacques; Colette Cywes; Richard B Sisson; Kol A Zarember; Paul J Godowski; Jennifer L Christianson; Hilde-Kari Guttormsen; Michael C Carroll; Anne Nicholson-Weller; Michael R Wessels
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

7.  Genetically distinct Group B Streptococcus strains induce varying macrophage cytokine responses.

Authors:  Rebecca A Flaherty; Elena C Borges; Jessica A Sutton; David M Aronoff; Jennifer A Gaddy; Margaret G Petroff; Shannon D Manning
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.